Episode Details

The United States stands at a pivotal juncture in eliminating HIV. Despite recent advancements, including the development of an effective new form of pre-exposure prophylaxis (PrEP), an uncertain future marked by cuts to Medicaid and research hurdles threatens to undo the country’s progress. In this episode: Jeremiah Johnson, Executive Director of PrEP4All, sheds light on the urgent need for equitable access to PrEP and what’s at stake if we fail to scale up initiatives to test, prevent, and treat HIV.

Jeremiah Johnson is the Executive Director of PrEP4All—an organization that seeks to prevent the spread of HIV by identifying data-driven policy solutions to increase access to PrEP.

Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland’s Health Department.

• Trump’s Policies Could Undermine the Fight to End America’s HIV Epidemic—Tradeoffs

• FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option—CNBC

• Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic—Journal of Law, Medicine & Ethics

• A National PrEP Program to End the Nation’s HIV Epidemic—Public Health On Call (April 2022)